secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097535
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q4 net loss $12.9M; cash $107.6M; ceases POTENTIATE enrollment; BBI-940 trial enrolling
--------------------------------------------------------------------------------

- Net loss of $12.9M for Q4 2025 and $58.2M for FY2025, vs $16.4M and $65.4M in same periods of 2024.
- Cash, cash equivalents, and short-term investments total $107.6M; expected runway into H2 2028 through initial proof-of-concept readout for KOMODO-1.
- Ceased enrollment in Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) due to market considerations and prioritization of BBI-940 program.
- KOMODO-1 first-in-human trial of BBI-940 (oral Kinesin degrader) open for enrollment in ER+/HER2- and TNBC-LAR breast cancer.
- Director Christine Brennan resigned effective March 3, 2026 due to new role at Johnson & Johnson Development Corp., no disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000119312526097535/0001193125-26-097535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000119312526097535/bold-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer